“Retirement Secret” Showed 995% Gain Last Time We Shared It

See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)

Mark Van Oene Biography and Net Worth

SVP of Illumina

Mark Van Oene is the Senior Vice President, Chief Commercial Officer of Illumina, Inc. Mr. Van Oenewas previously the Company's Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. He will be responsible for worldwide sales, services, and marketing at the Company.

What is Mark Van Oene's net worth?: The estimated net worth of Mark Van Oene is at least $107.71 million as of February 16th, 2024. Mr. Van Oene owns 876,611 shares of Illumina stock worth more than $107,709,194 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Van Oene may own. Learn More about Mark Van Oene's net worth.
How do I contact Mark Van Oene?: The corporate mailing address for Mr. Van Oene and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Mark Van Oene's contact information.
Has Mark Van Oene been buying or selling shares of Illumina?: Mark Van Oene has not been actively trading shares of Illumina during the last ninety days. Most recently, Oene Mark Van sold 625 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $355.13, for a transaction totalling $221,956.25. Learn More on Mark Van Oene's trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. In the last year, insiders at the life sciences company sold shares 4 times. They sold a total of 1,815 shares worth more than $314,104.60. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 2/22/2024.

Mark Van Oene Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2020	Sell	625	$355.13	$221,956.25
5/1/2020	Sell	625	$316.83	$198,018.75	20,230
2/5/2020	Sell	625	$300.24	$187,650.00
1/2/2020	Sell	625	$330.99	$206,868.75	11,578
10/1/2019	Sell	625	$304.84	$190,525.00	14,209
11/5/2018	Sell	6,835	$326.11	$2,228,961.85	17,126
9/4/2018	Sell	1,091	$354.18	$386,410.38	11,126
4/12/2018	Sell	1,400	$238.48	$333,872.00	12,217
2/16/2018	Sell	1,408	$228.85	$322,220.80	15,760
11/15/2017	Sell	1,250	$207.76	$259,700.00	11,691
11/13/2017	Sell	1,232	$207.78	$255,984.96	11,691
10/12/2017	Sell	1,250	$207.21	$259,012.50
9/12/2017	Sell	9,729	$211.33	$2,056,029.57	24,908

Mark Van Oene Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $117.25

$116.91

$122.04

50 Day Range

MA: $132.44

$116.69

$146.07

2 Week Range

Now: $117.25

$89.00

$217.60

Volume

270,574 shs

Average Volume

1,720,465 shs

Market Capitalization

$18.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

“Retirement Secret” Showed 995% Gain Last Time We Shared It

From Stansberry Research | Ad

Get the free details now.